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Introduction
Angiogenesis is an important physiological event, consisting of
the formation of new blood vessels from the preexisting
microvasculature network, and is also involved in pathological
processes such as inflammation, tumor growth, and metastasis.
Tumor angiogenesis plays a key role in cancer development, as
neovascularization is necessary to supply oxygen and nutrients
in order to support tumor cell proliferation.[1] Substances capa-
ble of blocking tumor-related angiogenesis and, therefore, re-
tarding cancer progression are termed antiangiogenic agents.
Angiogenesis is regulated by a number of receptors, whose
expression is related to the conditions of the cell environment,
such as pH and supply of oxygen and nutrients.[1c] Among the
proteins involved in the angiogenic process, integrins play an
important role by promoting endothelial cell attachment and
migration onto the surrounding extracellular matrix, cell-to-cell
interaction, and intracellular signal transduction.[2] Integrins are
heterodimeric glycoproteins composed of two noncovalently
associated a and b transmembrane subunits, which recognize
and bind their ligands through contiguous tripeptide sequen-
ces. The recognition motif Arg-Gly-Asp (RGD) allows endoge-
nous ligands to interact with several integrins (e.g. aVb3, aVb5,
and a5b1) that are very important for tumor progression, meta-
stasis, and angiogenesis.[3] A number of peptide and peptido-
mimetic integrin ligands containing the RGD sequence have
been developed, some of which display a strong affinity to-
wards these receptors.[4] X-ray analysis of integrin avb3 cocrys-
tallized with the cyclic RGD pentapeptide cyclo-[Arg-Gly-Asp-d-
Phe-N(Me)-Val] , Cilengitide, provided the structural basis to ra-
tionalize the observed binding properties.[5] Activity and selec-
A dual-action ligand targeting both integrin aVb3 and vascular
endothelial growth factor receptors (VEGFRs), was synthesized
via conjugation of a cyclic peptidomimetic aVb3 Arg-Gly-Asp
(RGD) ligand with a decapentapeptide. The latter was obtained
from a known VEGFR antagonist by acetylation at the Lys13
side chain. Functionalization of the precursor ligands was car-
ried out in solution and in the solid phase, affording two frag-
ments: an alkyne VEGFR ligand and the azide integrin aVb3
ligand, which were conjugated by click chemistry. Circular di-
chroism studies confirmed that both the RGD and VEGFR
ligand portions of the dual-action compound substantially
adopt the biologically active conformation. In vitro binding
assays on isolated integrin aVb3 and VEGFR-1 showed that the
dual-action conjugate retains a good level of affinity for both
its target receptors, although with one order of magnitude
(10/20 times) decrease in potency. The dual-action ligand
strongly inhibited the VEGF-induced morphogenesis in Human
Umbilical Vein Endothelial Cells (HUVECs). Remarkably, its effi-
ciency in preventing the formation of new blood vessels was
similar to that of the original individual ligands, despite the
worse affinity towards integrin aVb3 and VEGFR-1.
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tivity of these integrin ligands are linked to an extended con-
formation of the RGD sequence, with a distance of about 9 æ
between the Cb atom of aspartic acid and arginine residues,
whose side chains form an “electrostatic clamp”[5] crucial for
ligand binding to the integrin receptor.
Our research group has recently reported a library of new
cyclic RGD peptidomimetic integrin ligands, containing bifunc-
tional diketopiperazine (DKP) scaffolds,[6] that displayed low
nanomolar IC50 values in inhibiting the binding of biotinylated
vitronectin to integrin aVb3. In vitro biological studies per-
formed on compound 1 (Figure 1) showed that this ligand is
able to inhibit angiogenesis in Human Umbilical Vein Endothe-
lial Cells (HUVEC), both under basal conditions and in the pres-
ence of pro-angiogenic growth factors[7] or of pro-inflammato-
ry chemokine interleukin-8 (IL-8).[8]
The observed antiangiogenic activity was likely due to the
disruption of endothelial cell–extracellular matrix attachment,
induced by integrin engagement by compound 1. This was fur-
ther confirmed by the inhibition of the phosphorylation of Akt,
a serine/threonine-specific protein kinase that plays a key role
in the regulation of vascular homeostasis and angiogenesis.
Unlike angiogenesis, other parameters such as cell viability, cell
proliferation, and mRNA levels of aV, b3, or b5 integrin subunits
were not affected by the administration of compound 1.[8, 9]
Other cell surface receptors besides integrins are involved in
tumor angiogenesis, and the
pathways mediated by the dif-
ferent receptors are deeply inter-
twined. Such a “crosstalk” stimu-
lates the angiogenic process
through both direct and indirect
association of the involved re-
ceptors. Interactions between in-
tegrins and vascular endothelial
growth factor receptors (VEGFRs)
have been investigated and sug-
gested to be crucial for tumor
growth and invasion.[10] VEGFRs
are members of the receptor ty-
rosine kinase (RTK) superfamily,
and their dimerization and acti-
vation are induced by the bind-
ing of endogenous homodimeric vascular endothelial growth
factors (VEGF) to the receptor extracellular domain. The biolog-
ical activity of the VEGF–VEGFR system is closely related to
tumor angiogenesis and progression: the hypoxic conditions
present in tumors induce both VEGF gene expression and up-
regulation of VEGFRs.[11] Small molecule inhibitors of VEGF-A
receptor tyrosine kinase (receptor intracellular segments) have
been shown to inhibit the biological function of this growth
factor and are currently being used as drugs (Sorafenib and Su-
nitinib) for antiangiogenic therapy.[12] Other inhibitors of the
VEGF’s biological activity interact with the VEGFRs’ extracellular
segment, and most members of the latter family are peptides
or peptidomimetics. Among them, it is worth mentioning the
peptoid ligands developed by Kodadek and co-workers,[13] the
helical peptides derived from VEGF,[14] and Vammin hotspots,[15]
a 17-amino acid cyclopeptide that was isolated from a phage
display library.[16]
The reported colocalization of integrin aVb3 and VEGFR on
the surface of HUVEC upon VEGF stimulation demonstrates
that a “crosstalk” between these receptors occurs.[10f] Following
these findings, in a pioneering study, Cochran and co-workers
reported that a dual specific fusion protein was able to bind si-
multaneously integrin aVb3 and VEGFR-2, and to inhibit VEGF-
mediated capillary tube formation in HUVEC and murine blood
vessel formation within implanted Matrigel plugs.[17a] Inspired
by this contribution, we speculated that a dual-action integ-
rin–VEGFR small molecule ligand could also represent a novel
antiangiogenic and antitumor strategy offering more effective
multiple targeting to tumor cells and tumor vasculature.[17b] We
thus designed a new dual-action ligand (compound 5 in
Figure 2) targeting integrin aVb3 and VEGFR. As integrin bind-
ing moiety, we exploited cyclo[DKP-RGD]-CH2NH2 (2) (Figure 1),
a functionalized analog of ligand 1 that we had previously
used for conjugation to paclitaxel[18] and SMAC mimetic mole-
cules.[19] As VEGFR ligand moiety we selected the a-helical de-
capentapeptide 3 (Figure 2), recently reported by D’Andrea
and co-workers,[14] because of its simple preparation and effica-
cy in inhibiting angiogenesis in vivo. However, for conjugation
to compound 2 we employed compound 4 (Figure 2), a deriva-
tive of 3 acetylated at the Lys13 side chain,[20] in order to avoid
Figure 1. The potent and selective integrin aVb3 ligand cyclo[DKP-RGD] (1),
and its derivative cyclo[DKP-RGD]-CH2NH2 (2).
Figure 2. The a-helical peptide 3, its derivative 4, and the novel small-molecule dual-action ligand 5.
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any possible interference of the Lys13 free amino group with
the “electrostatic clamp” used by the cyclo[DKP-RGD] moiety
for binding to its aVb3 integrin target. Previous studies clearly
demonstrated that neither the N-terminal Lys1 side chain nor
the Lys13 side chain are involved in receptor recognition.[14b]
Accordingly, while both positions could in principle be exploit-
ed for conjugation, in this paper we used the N-terminal Lys1
side chain.
Results and Discussion
Synthesis of the dual-action compound 5
The dual-action ligand 5 (Figure 2) was obtained from the two
fragments 6 and 7, that were joined by copper-catalyzed
azide-alkyne cycloaddition (CuAAC) reaction (Scheme 1).
Alkyne 6 was obtained from the resin-supported peptide 8,
which was readily synthesized by microwave-assisted solid
phase peptide synthesis (SPPS). Treating the on-bead
decapentapeptide resin with a 94:5:1 dichlorome-
thane/triisopropylsilane/trifluoroacetic acid (v/v/v)
cleavage mixture resulted in the selective removal of
4-methyltrityl (Mtt) protecting group from Lys1 side
chain. The free amine moiety in 9 was reacted on
solid phase with 4-pentinoyc acid, after activation of
the carboxylic acid moiety in the presence of the
condensing agents, 1-[bis(dimethylamino)methylene]-
1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluoro-
phosphate (HATU) and 1-hydroxy-7-azabenzotriazole
(HOAt), and N,N-diisopropylethylamine (DIPEA) as
base, obtaining fragment 6. Fragment 7 was prepared starting
from the commercially available bifunctional PEG8 com-
pound 10 (Figure 3A), which was selected because of its mon-
odisperse structure profile.[21] Amino azide 10 was first elongat-
ed with succinic anhydride, affording the azido acid 11. Cy-
clo[DKP-RGD]-CH2NH2 2 (Figure 1) was coupled with the spacer
11 in acetonitrile/phosphate buffer, controlling the pH of the
medium in order to have the free benzylic amine of 2 acting
as nucleophile. Finally, the synthesis of the dual-action ligand 5
was achieved by coupling fragments 6 and 7 on solid phase
via CuAAC reaction in the presence of copper iodide and
sodium ascorbate, and then by cleaving the adduct 12 from
the resin.
The 39-atom-long linker system of conjugate 5 (Figure 3B) is
of length commensurate with the linker used by Cochran and
co-workers for their dual-specific proteins (14 amino acid resi-
dues, that is, 42 atoms, between the two ligand moieties).[17a]
The decapentapeptide 4 (Figure 2), used as a reference com-
Figure 3. Bifunctional PEG8 amino azide 10 (A), and the distance between the two ligand
moieties of conjugate 5 (B).
Scheme 1. Reagents and conditions : a) SPPS: 1) 25% piperidine in DMF, 2) Fmoc-AA-OH (4 eq), DIC, HOAt, DIPEA, DMF, 3) 25% Ac2O in DMF; b) CH2Cl2/TIS/TFA
94:5:1 v/v/v, r.t. , 12Õ2 min; c) 4-pentynoic acid, HATU, HOAt, DIPEA, DMF, r.t. , o/n; d) succinic anhydride, DMAP, DIPEA, CH2Cl2, r.t. , 18 h, 96%; e) N-hydroxysuc-
cinimide, DIC, DMF, r.t. , 2 h, then 2, CH3CN, phosphate buffer, pH 7.3–7.6, 0 8C, 18 h, 65% over 2 steps; f) 6+7, CuI, sodium ascorbate, DIPEA, DMF, 72 h, r.t. ;
g) TFA/EDT/H2O/TIS 94:2.5:2.5:1 v/v/v/v, 3 h, r.t. , 5% (4, over 16 steps) and 6% (5, over 19 steps). Mtt=4-methyltrityl.
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pound, was synthesized by cleaving peptide 8 from the resin.
The nonacetylated peptide 3 was also synthesized by SPPS,
with a procedure similar to the one followed for compound 4
(see the Supporting Information for details).
Structural investigation of the synthesized compounds
The circular dichroism (CD) spectrum of peptide 4 measured in
water (Figure 4) is consistent with that published by D’Andrea
and co-workers for the parent peptide 3.[14] The position and
the intensities of the two negative maxima indicate the pres-
ence of a relevant population of a-helical structures. However,
the negative maximum of the amide p!p* electronic transi-
tion, located at 203 nm, is significantly blue-shifted with re-
spect to the canonical position (208 nm) of an a-helical confor-
mation. This finding, together with the intensity decrease of
the band at about 222 nm, can be safely assigned to a non-
negligible participation of unordered conformations, also
called “polyproline type-II”. We extended our analysis to two
additional solvents, namely trifluoroethanol (TFE) and metha-
nol, roughly mimicking the hydrophobic biological environ-
ment in which the peptide would probably display its
action.[22] These CD spectra (Figure 4) are characterized by two
negative maxima typical of an a-helical conformation. This in-
crease in the helical content, moving from water to the alco-
holic solvents, clearly indicates that peptide 4 is not very rigid,
as its 3D-structure is highly dependent on the environment.
The same is true for the parent peptide 3, whose CD spectra
undergo a parallel modification in the cited solvents (see the
Supporting Information).
These conclusions, based on the analysis of the amide ab-
sorption region (190–250 nm), must be taken with caution as
the aromatic chromophores of Tyr and Trp may contribute in
an unpredictable way. Indeed, despite being achiral, they
might display induced CD signals, whose intensities depend
on the rigidity of the molecule. To evaluate this possible inter-
ference, we analyzed the region above 250 nm, where the
amide absorption is negligible. In the UV absorption spectra of
peptides 3 and 4, recorded at the same peptide concentration
of the CD measurements, a band centered at 275 nm is clearly
visible in all solvents investigated (data not shown). Conversely,
in the corresponding CD spectra, no bands above 250 nm
could be detected. On this basis, we can conclude that the
contribution of the aromatic moieties to the CD curves is mar-
ginal.
The ratio R between the ellipticity values (q) of the two neg-
ative maxima (R= [q]222/[q]208) can be used to discriminate the
contribution to the CD curves of a- and 310-helical structures.
[22]
In particular, an R value smaller than 0.5 is diagnostic of an im-
portant contribution from 310-helical conformations, while
a value closer to 1 is indicative of an a-helical structure. The R
value of peptide 4 in water is not significant because, as stated
above, the wavelengths of the negative maxima in this solvent
are too far from those of a canonical helix. In TFE and in meth-
anol the R values are 0.84 and 0.86, respectively, thus high-
lighting the presence of a predominantly a-helical conforma-
tion.
The CD spectra in water of compounds 2 and 7 are shown
in Figure 5. The two curves have trends usually attributed to
type b folding, in particular b-turn type II, characterized by two
maxima: a positive maximum at 203 nm and a negative one
at 226 nm. Similar spectra were observed in cyclic tripeptides
known to adopt b-turn structures. Interestingly, the relatively
modest differences of the two curves suggest that the PEG8
moiety does not alter significantly the structure of com-
pound 7 with respect to the precursor molecule 2.
In a previous work, this class of compounds was already
demonstrated via NMR and computational studies to adopt
a b-turn-like conformation (Figure 6).[6]
In Figure 7, the CD spectrum of 5 and the spectrum ob-
tained by the algebraic sum of the spectra of 4 and 7 are
reported.
As the two spectra display rather similar features (band posi-
tion, sign, and intensity), we tentatively conclude that no dra-
matic conformational changes occur. However, we cannot ex-
clude the intervention of minor but significant structure modi-
fications. The CD lineshape of the dual ligand 5 changes when
water is replaced by either TFE or methanol (Figure 8), some-
how mirroring the behavior of 4 (Figure 4). Therefore, this
Figure 4. CD spectra of peptide 4 in water, 2,2,2-trifluoroethanol (TFE) and
methanol (MeOH) (0.1 mm).
Figure 5. CD spectrum of 2 (left) and 7 (right) in H2O (0.1 mm).
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change in the CD pattern should be ascribed mainly to pep-
tide 4. Indeed, in a comparative analysis we observed that the
conformation of the cyclic, constrained, RGD ligand is not af-
fected by the solvent (Supporting Information). In summary,
the conformational behavior of the two isolated ligands is not
substantially altered upon conjugation in the dual ligand 5.
Yet, even minor structural changes can somehow impact on
highly stereospecific activities such as receptor binding.
Biological studies
In vitro binding assays on isolated integrins and VEGF recep-
tor
The binding of the dual-action ligand 5 to the isolated integrin
and VEGF receptors was measured. In the case of integrins, the
ability of compound 5 to inhibit biotinylated vitronectin bind-
ing to the purified aVb3 and aVb5 extra-cellular integrin do-
mains (IC50) was determined and compared with that of refer-
ence compounds 1[6b] and cyclo[RGDfV] 13 (Figure 9).[23]
Similar to its parent ligand 1, conjugate 5 showed a remark-
able selectivity for integrin aVb3 compared with aVb5 (Table 1).
In the case of 5, the affinity for integrin aVb3 remained in the
nanomolar range, although it was about 20 times worse than
that of unconjugated ligand 1, possibly because of the in-
creased steric hindrance or of interference with the decapenta-
peptide VEGFR ligand. These binding experiments demonstrate
that the cyclo[DKP-RGD] moiety retains its ability to bind to
the aVb3 integrin receptor, even after conjugation.
The conjugate ligand 5, together with the VEGFR ligands 3
and 4, were also evaluated for their ability to compete with
biotinylated VEGF165 for the binding to the extracellular
domain (D1–D7) of recombinant VEGFR-1. The test was accom-
Figure 6. The preferred intramolecular hydrogen-bonded pattern proposed
for compound 1 on the basis of NMR spectroscopic data. The arrow indi-
cates a significant nuclear Overhauser effect (NOE) contact. Computational
studies assessed that more than 90% of the conformations sampled during
restrained mixed-mode Metropolis Monte Carlo/Stochastic Dynamics simula-
tions adopted an extended arrangement of the RGD sequence characterized
by a pseudo-b-turn type II at DKP¢Arg and the formation of the correspond-
ing hydrogen bond between the NH¢Gly and C(5)=O.
Figure 7. CD spectrum of 5 (solid line) in H2O (0.1 mm) superimposed to the
sum CD spectrum of 4+7 (dashed line).
Figure 8. CD spectra of 5 in TFE, MeOH and H2O (0.1 mm).
Figure 9. The potent aVb3 integrin ligand c[RGDfV] (13) (see Ref. [23]).
Table 1. In vitro binding assays on isolated aVb3 and aVb5 receptors.
IC50 [nm]
[a]
Compound aVb3 aVb5
5 97.530.8 41001800
1[b] 4.51.1 14925
13[b] 3.21.3 7.54.8
[a] IC50 values were calculated as the concentration of compound re-
quired for 50% inhibition of biotinylated vitronectin binding as estimated
by GraphPad Prism software; all values are the arithmetic meanSD of
triplicate determinations. [b] Ref. [6b].
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plished according to the procedure reported by Vidal, Inguim-
bert, and co-workers.[15,24] Unlabelled VEGF165, used as reference
compound, showed an IC50 value of 146 pm, comparable with
the value reported by the same authors.[24]
Unfortunately, for compounds 3 and 4, it was not possible
to obtain a dose-response curve because, at high concentra-
tions (above 0.1 mm), the wells showed an anomalously high
chemiluminescence readout (even higher than that of the posi-
tive control). In this way, we could only observe the initial in-
hibition of the binding of biotinylated VEGF165 by com-
pounds 3 and 4 at 10 mm concentration. The reasons for this
behavior are currently unclear, and modifications in the sample
preparation protocol (e.g. change of the amount of dimethyl-
sulfoxide, DMSO, used for solubilizing the peptide) did not
solve the problem. It should be noted that the IC50 binding
value of compound 3 to VEGFR-1 reported in the literature
was not determined with this kind of competitive binding pro-
tocol. Rather, the affinity value was measured by NMR titration
on VEGFR-1D2 (Kd=46 mm).
[14b]
The dual-action compound 5 did not show this anomalous
behavior in competitive binding assay, and its affinity towards
VEGFR-1 was determined as 57%10% inhibition at 500 mm
concentration. Therefore, conjugate 5 is about ten times less
potent than peptide 3 (or its acetylated derivative 4) in inhibit-
ing VEGF binding to VEGFR-1. In summary, dual-action com-
pound 5 showed affinity towards both its receptor targets (in-
tegrin aVb3 and VEGFR-1), although with one order of magni-
tude (10/20 times) loss of potency.
In vitro morphogenesis assays on HUVEC
HUVECs represent a valid in vitro model providing seminal in-
sights into the cellular and molecular events leading to neo-
vascularization in response to inflammation and hypoxia in
cancer, ischemic events, and in embryogenesis.[25] Integrins
aVb3 and aVb5 are expressed on HUVEC
[26] and these human
endothelial-derived cells represent a suitable model to investi-
gate the effects of integrin ligands on angiogenesis.
To assess the activity of the compounds targeting only one
cell surface receptor, namely integrin ligand 1 and VEGFR li-
gands 3 and 4, as well as the dual-action ligand 5, HUVEC
were incubated with these compounds under basal (absence
of stimuli) or stimulated (VEGF165) conditions. Under basal con-
ditions, HUVEC did not show any network formation, but the
addition of VEGF165 induced significant morphogenesis (Fig-
ure 10A). The addition of integrin ligand 1, VEGFR ligands 3
and 4 and dual-action ligand 5 markedly decreased the new
capillary network formation (see for instance Figure 10B)
whereas the addition of negative control 14 (Ac-Lys-Gln-Met-
Tyr-Leu-Glu-Leu-Gly-Tyr-Ala-Thr-Ile-Lys-Trp-Leu-amide), a pep-
tide containing the same amino acids as 3 and 4 but in
a scrambled sequence, did not affect morphogenesis to a sig-
nificant extent (Figure 10C).
A dose-response study (Figure 11) revealed that all the
tested ligands display a similar profile of activity, reducing the
morphogenesis already at nanomolar concentration. This effect
is in agreement with previous reports using ligand 1 on
HUVEC, albeit with different stimuli,[8] and ligand 3.[14] Interest-
ingly, also peptide 4, bearing an acetyl group at the nitrogen
atom of Lys13 side chain, proved capable of inhibiting angio-
genesis with an efficacy similar to that of its parent compound
3 (Figure 11C). Therefore, Lys13 side chain acetylation does not
affect significantly the biological properties of peptide 3. The
dual-action compound 5 (Figure 11D) proved comparably
active, inhibiting morphogenesis in HUVECs with a similar con-
centration profile and effect: all the ligands tested decreased
the length of branches in newly formed vessels to a 40% with
respect to the stimulation with VEGF (Figure 12). In addition,
the co-administration of ligands 1 and 4 was investigated (Fig-
ure 11E). Also in this case no difference in concentration and
effect profile could be noticed. Finally, the scrambled peptide
14 (negative control), tested at the 1 mm concentration, did
not significantly affect VEGF-induced morphogenesis (82%
21% of VEGF alone, calculated probability value p>0.05) and
confirmed that the effects observed for all the other com-
pounds are due to their specific interaction with the targeted
receptors. The overall picture designed by these data refers to
a very active set of ligands which, once combined in a dual-
action system fully retain the antiangiogenic activity. Remarka-
bly, the efficiency of the dual-action ligand 5 in preventing the
formation of new blood vessels was comparable to that of li-
gands 1 and 4, singly or jointly administered, despite its worse
affinity towards integrin aVb3 and VEGFR-1 (one order of mag-
nitude loss of potency). This finding might be interpreted as
the result of a synergy between the two covalently linked
binding motifs, in analogy with the results on fusion proteins
in which the mutated protein containing both the VEGFR and
integrin binding sequences displayed a more pronounced
effect of morphogenesis inhibition in HUVEC.[17a]
Conclusions
Tumor angiogenesis is a crucial phenomenon for cancer devel-
opment and metastasis, and is regulated by a number of cell
surface receptors, such as integrin aVb3 and VEGFRs, which are
known to specifically interact (receptor–receptor “crosstalk”). A
dual-action ligand 5 was synthesized via conjugation of the
potent peptidomimetic aVb3 RGD ligand 1 with the decapenta-
peptide 4, a derivative acetylated at the Lys13 side chain of
known peptide 3, a VEGF receptor antagonist with antiangio-
genic activity. Ligand 5, targeting both integrin aVb3 and
VEGFRs, was designed with the aim of inhibiting both recep-
Figure 10. Representative phase contrast photomicrographs of HUVEC
plated on Matrigel in the presence of: A) VEGF165 (10 ngmL
¢1) ; B) VEGF165
(10 ngmL¢1)+5 (1 mm) ; C) VEGF165 (10 ngmL
¢1)+14 (1 mm). Images were
elaborated by phase-contrast microscopy using a fluorescence microscope.
Frames are approximately 10 mm wide Õ 10 mm tall.
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tors and possibly blocking their
“crosstalk”. The secondary struc-
ture of dual-action ligand 5 was
studied by circular dichroism
spectroscopy, and both the RGD
portion and the decapentapep-
tide in the conjugate were
found to substantially retain
their respective conformations.
However, even minor structural
changes can somehow impact
on highly stereospecific activities
such as receptor binding.
Dual-action ligand 5 was
tested in vitro for its ability to
bind to isolated integrin aVb3
and VEGFR-1 receptors. Conju-
gate 5 showed affinity towards
both its receptor targets (integ-
rin aVb3 and VEGFR-1), although
with one order of magnitude
(10/20 times) loss of potency
compared to ligands 1 and 4,
targeting only one receptor.
Conjugate 5 showed a potent
antiangiogenic activity in VEGF-
stimulated morphogenesis
assays on HUVEC. Remarkably, its
efficiency in preventing the for-
mation of new blood vessels
was similar to that of ligands
1 and 4, singly or jointly admin-
istered, despite its worse affinity
towards integrin aVb3 and
VEGFR-1. This finding might be
interpreted as the result of a syn-
ergy between the two covalently
linked binding motifs.[17a] Howev-
er, in this particular case (no real advantage in the morphogen-
esis assays over ligands 1 and 4), the extra effort for the syn-
thesis of conjugate 5 is not justified, and further investigations
are necessary to: 1) design and develop more efficient dual-
action compounds targeting integrins and VEGFR and 2) con-
firm the beneficial effect of a dual ligand with in vivo experi-
ments.
Experimental Section
The detailed procedure for the synthesis of compounds 1 and 2,
and for conjugation of 2 to other molecular entities was previously
described.[6b,18]
Solid phase peptide synthesis (SPPS): The SPPS was accomplished
using the semiautomatic synthesizer Biotage Initiator (Uppsala,
Sweden) assisted by microwaves; fluorenylmethyloxycarbonyl
(Fmoc) strategy and Rink amide MHBA resin (100–200 mesh; load-
ing: 0.5 mmolg¢1) were used. Each coupling step consisted of
1) activation of the Fmoc-protected amino acid, 2) addition of the
Figure 11. Effect of incubation of HUVEC for 5 h with the ligands 1 (A), 3 (B), 4 (C), 5 (D), and 1+4 (E) on VEGF-in-
duced morphogenesis. Tube formation was evaluated as length of branches. Data are presented as meanS.D. of
4–10 separate experiments (*=p<0.05 and **=p<0.01 vs. VEGF alone).
Figure 12. Inhibitory effects exerted by incubation with the different ligands
on VEGF-induced morphogenesis. Results are presented as % of the effect
normalized to VEGF alone and data are expressed as meanS.D. for 4–
10 separate experiments.
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activated amino acid to the resin in the synthesizer, in order to per-
form the coupling reaction, and 3) capping, deprotection, and
washing steps.
Resin preparation and storage : Before starting the SPPS, the resin
was swollen in dimethylformamide (DMF) (3.0 mL) at r.t. for 45 min,
then the solvent was drained. Two deprotection steps were carried
out adding 25% piperidine in DMF (3.0 mL for each step) to the
beads: the reaction was performed at r.t. under inert atmosphere
for 5 min and 15 min for the first and the second deprotection
step, respectively. The resin was then washed with DMF. At the
end of each step, the liquid phase was drained. Whenever it was
necessary to stop the SPPS, the beads were stored in DMF (2–
3 mL) at ¢20 8C, with the terminal amino group of the peptide left
Fmoc-protected.
General procedure for Fmoc-AA-OH activation and coupling
cycle : To a solution of the desired Fmoc-AA-OH (4.0 eq with re-
spect to the resin) in DMF (3.5 mL) DIC (4.0 eq), HOAt (4.0 eq) and
DIPEA (8.0 eq) were added successively at 0 8C, under stirring and
inert atmosphere. After 25 min, the reaction mixture was added to
the resin in the reaction vessel of the synthesizer, and a cycle of
coupling–capping–deprotection–washing was effected. At the end
of the cycle, it is possible to add another residue or to effect a cap-
ping–washing cycle if the peptide sequence is complete.
General procedure for Kaiser test : A few resin beads were taken
and put in a glass test tube. The beads were washed with EtOH,
then three drops of each of the following solutions were added:
1) 80% phenol in EtOH, 2) KCN in pyridine [prepared by diluting
a 0.1 mm aqueous solution of KCN with pyridine (2% v/v)] , and
3) 6% ninhydrin in EtOH. The mixture was shaken and heated in
a water bath. The resin beads and the solution turned dark blue
when a free primary amine was present (positive result). Resin
beads and solution maintained their yellow color when free pri-
mary amino groups were absent (negative result).
General procedure for final cleavage and deprotection : The pro-
tected-on-beads peptide was swollen first with DMF (3.5 mL), then
with CH2Cl2 (3.5 mL). The beads were treated three times with the
cleavage cocktail 94:2.5:2.5:1 TFA/H2O/EDT/TIS (v/v/v/v). After 1 h,
the liquid was filtered off under nitrogen flow and collected in
a round-bottom flask. The combined filtered fractions were con-
centrated and poured in cold diethyl ether, provoking precipitation
of the product. Diethyl ether was removed with a syringe, afford-
ing the crude product, which was purified with reverse-phase
HPLC.
Circular dichroism spectroscopy : The CD measurements were reg-
istered on a Jasco J-715 instrument (Easton, USA) with Hellma
0.1 cm quartz cell in milliQ H2O as solvent. The spectra were elabo-
rated with Origin and the Jasco instrument associated software.
The values are reported as total molar ellipticity [q]T (degÕcm
2Õ
dmol¢1).
Solid-phase receptor-binding assays on integrin receptors : Puri-
fied aVb3 and aVb5 receptors (Chemicon International, Inc. , Temecu-
la, USA) were diluted to 0.5 mgmL¢1 in coating buffer containing
20 mmolL¢1 Tris-HCl (pH 7.4), 150 mmolL¢1 NaCl, 1 mmolL¢1
MnCl2, 2 mmolL
¢1 CaCl2, and 1 mmolL
¢1 MgCl2. An aliquot of dilut-
ed receptors (100 mL/well) was added to 96-well microtiter plates
(NUNC MW 96F Maxisorp Straight) and incubated overnight at
4 8C. The plates were then incubated with blocking solution (coat-
ing buffer plus 1% bovine serum albumin) for additional 2 h at r.t.
to block nonspecific binding followed by 3 h-incubation at r.t. with
various concentrations (10¢12–10¢5m) of test compounds in the
presence of 1 mgmL¢1 vitronectin biotinylated using EZ-Link Sulfo-
NHS-Biotynilation kit (Pierce, Rockford, USA). After washing, the
plates were incubated for 1 h at r.t. with streptavidin-biotinylated
peroxidase complex (Amersham Biosciences, Uppsala, Sweden) fol-
lowed by 30 min incubation with Substrate Reagent Solution
(100 mL, R&D Systems, Minneapolis, USA) before stopping the reac-
tion by addition of 2n H2SO4 (50 mL) Absorbance at 415 nm was
read in a Synergy HT Multi-Detection Microplate Reader (BioTek In-
struments, Inc. , Winooski, USA). Each data point is the result of the
average of triplicate wells and was analyzed by nonlinear regres-
sion analysis with Prism software version 5 (GraphPad Software,
Inc. , La Jolla, USA).
Solid-phase receptor-binding assays on VEGFR-1: The surface of
white high-binding 96-well microplates (Corning Life Sciences,
Netherlands) was coated with of phosphate-buffered saline solu-
tion (100 mL, PBS, pH 7.4) containing 200 ngmL¢1 of VEGFR-1 ECD/
Fc chimera (R&D Systems, Minneapolis, USA) and incubated over-
night at 4 8C. After three washes with PBS 0.1%, (150 mL, v/v)
Tween 20 (buffer A), the plate was blocked by PBS (160 mL) with
3% (w/v) of BSA and incubated at r.t. for 2 h. The plate was
washed three times with buffer A. Then, 100 mL of a solution of
btVEGF165 at 131 pm (5 ngmL
¢1) and the tested compounds at vari-
ous concentrations diluted in PBS containing 5% DMSO were
added to each well. After 3 h at 37 8C, the plate was washed three
times with buffer A and streptavidin-horseradish peroxidase
(100 mL) diluted at 1:1000 in PBS containing 0.1% (v/v) Tween 20
and 0.3% (w/v) BSA were added per well. After 1 h of incubation
at r.t. , the plate was washed five times with buffer A (150 mL), and
SuperSignal West Pico Chemiluminescent Substrate (100 mL, Pierce,
Rockford, USA) was added. The remaining bt-VEGF165 was detected
by chemiluminescence, which was quantified with a Synergy HT
Multi-Detection Microplate Reader (BioTek Instruments, Inc. , Wi-
nooski, USA). The percentages of btVEGF165 displacement were cal-
culated by the following formula: percentage of displacement=
100Õ[1¢(S¢NS)/(MS¢NS)] , where S is the signal measured, NS is
the nonspecific binding signal, and MS is the maximum binding
signal observed with btVEGF165 without tested compounds.
Cell culture : HUVEC were cultured in a medium supplemented
with fetal bovine serum (FBS, 2%), l-glutamine (10 mm), heparin
sulfate (0.75 UmL¢1), VEGF (15 ngmL¢1), EGF (5 ngmL¢1), FGF2
(5 ngmL¢1), IGF-I (15 ngmL¢1), and ascorbic acid (50 mgmL¢1) at
37 8C, in a moist atmosphere of 5% CO2. HUVEC were used for the
experiment between passages 2 to 10.
In vitro morphogenesis assays on HUVEC : To assess antiangio-
genic activity, HUVEC (2.5Õ104 cells) were seeded in a 24-well plate
coated with 100 mL/well of Matrigel previously polymerized for 1 h
at 37 8C. Cells were then incubated for 5 h at 37 8C in a moist at-
mosphere of 5% CO2 without or with tested compounds under
either resting (cell cultured in EndoGRO medium alone, without
FBS and all the growth factors) or stimulated conditions (addition
of VEGF, 10 ngmL¢1). Network formation was evaluated by phase-
contrast microscopy using a fluorescence microscope (Axiovert
40CFL, Carl Zeiss S.p.A. , Milan, Italy). Network formation was finally
quantified in terms of total length of the branches. For the pur-
pose of the analysis, open ramifications were considered as
branches. The total branch length (pixels) was quantified using the
ImageJ image analysis software (http://rsbweb.nih.gov/ij/).
Statistical analysis : Data are shown as means standard deviation
(S.D.) unless indicated otherwise. Statistical significance of the dif-
ferences was assessed by two-tailed Student’s t test for paired
data. Calculations were performed using a commercial software
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(GraphPad Prism version 5.00 for Windows, GraphPad Software, La
Jolla, USA, www.graphpad.com).
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